ogs-news - 500 Beiträge pro Seite

[mathias]

ogs-news




Medarex and Oxford GlycoSciences Form Alliance to Develop Human Therapeutic
Antibody Products

Oxford, UK, and Princeton, New Jersey, 11 September 2000 — Oxford GlycoSciences Plc (LSE: OGS) and
Medarex, Inc. (Nasdaq: MEDX) announced today an alliance to develop novel therapeutics produced through the joint
application of Medarex`s fully human monoclonal antibody technology and OGS`s proprietary proteomics technology for
high-throughput protein analysis and target validation. Antibodies are increasingly being recognized as a rapid and efficient
way to move potential products from the lab to the market. Medarex and OGS expect the first joint product from an
OGS-discovered antigen to enter Medarex`s T-12 DevelopmentSM program in the near future and that the collaboration
may generate multiple product candidates a year thereafter.

The two companies plan to jointly discover, develop and commercialize fully human antibodies as therapeutics. The
parties expect OGS to provide up to 30 protein targets for cancer or other life threatening diseases to the collaboration.
The targets or antigens for the alliance will come from OGS`s proprietary proteomics platform. The initial antigens OGS
intends to put into the alliance are novel breast cancer proteins.

Under the terms of the collaboration, Medarex and OGS will share preclinical and clinical responsibilities, and the two
companies intend to jointly commercialise products resulting from the research programme. Medarex will make a $5
million equity investment in OGS.

"We are excited about this opportunity to couple our HuMAb-Mouse® with the cutting-edge proteomics technology offered
by OGS. We believe that the ability of OGS to focus directly on disease-associated proteins will provide high quality
targets for our antibody approach. The combination of these technologies is expected to result in the development of a
number of fully human antibody-based therapeutic products," said Donald L. Drakeman, President and CEO of Medarex.

"OGS is undertaking to discover and file patent applications on hundreds of novel targets with a specific focus on new
membrane antigens for each of the major cancers - breast, prostate, colorectal, lung, ovarian, pancreatic and leukemia.
The successful development of an antibody drug is critically dependant on the quality of the protein target and its
relevance to human disease. Our proteomics technology can rapidly and precisely identify proteins over expressed at the
surface of human cancer cells. Then the power of Medarex`s fully human monoclonal antibody technology and
manufacturing capabilities come into play and result in synergies from discovery to development. In collaboration with
Medarex, we are confident we can convert our growing portfolio of proprietary proteins into a substantial pipeline of
therapeutic human monoclonal antibody products," said Michael Kranda, CEO of OGS.

Medarex is a biopharmaceutical company developing monoclonal antibody-based therapeutics to fight cancer and other
life-threatening and debilitating diseases. Medarex has assembled a broad platform of patented technologies for antibody
discovery and development, including the HuMAb-Mouse® and TC Mouse™ systems for the creation of high-affinity, fully
human antibodies; T-12 DevelopmentSM offering the potential to move from target to trial in approximately 12 months; and
Trans-Phage TechnologySM combining high throughput screening with fully human antibody development. Medarex
creates and develops fully human antibodies for itself and others, offering a full range of antibody development capabilities,
including pre-clinical and clinical manufacturing services. Donald L. Drakeman, Medarex`s President and CEO, serves as
a member of the OGS board of directors. For more information about Medarex, visit its web site at www.medarex.com.

OGS is a proteomics-based drug discovery and development company, headquartered in Oxfordshire, UK, applying its
proteomics technology to pharmaceutical research and development. OGS has proteomics collaborations with a number
of major pharmaceutical companies, including programs with Pfizer, Merck, Bayer, Pioneer Hi-Bred/DuPont, Quintiles and
Incyte Genomics Inc.

OGS has drug discovery programs in oncology, inflammation and infectious disease. OGS has a growing clinical and
pre-clinical pipeline including OGT 918 (Vevesca™) which is in late stage clinical trials for the treatment of glycolipid
storage disease.

For Medarex: Except for the historical information presented herein, certain matters discussed in this press release are
forward-looking statements that are subject to unknown risks and uncertainties. These risks and uncertainties include, but
are not limited to, Medarex`s early stage of product development, history of operating losses and accumulated deficit,
dependence on strategic alliances and the development of therapeutic products under these alliances, government
regulation of the biopharmaceutical industry and other risks that may be detailed from time to time in Medarex`s periodic
reports and registration statements filed with the Securities and Exchange Commission.

For OGS: Some important facts that could cause actual results to vary significantly from management`s expectations
noted in these forward looking statements include government approvals, intellectual property positions and costs. OGT
918 is an investigational drug and has not received approval for marketing in any country.

Füralle ogs-Fans ma lwas positives
Gruß-Mathias

[mathias]

ogs läuft ganz gut,neue News




Oxford GlycoSciences plc and Cambridge Antibody Technology Announce Strategic
Alliance in Protein Microarrays

Oxford, UK 12th September 2000 — Oxford GlycoSciences plc (LSE: OGS) and Cambridge Antibody Technology
(CAT: LSE) today announced the formation of a collaboration to develop "protein chip" technology for detection of proteins
using antibody based microarrays.

The companies will combine their respective technologies, to develop a new protein detection and screening technology
based on antibody microarrays. OGS`s human protein libraries and CAT`s human antibody libraries will be analysed,
paired proteins and antibodies selected and microarrays developed based on OGS`s current protein microarray prototype
format. The goal is to create a new generation of protein detection technology with the speed, throughput and sensitivity to
serve the development of research tools, diagnostics and novel therapeutics. Each party will fund its own research
contribution.

Michael Kranda, CEO of OGS said, "With the Human Genome map in hand the spotlight has shifted to proteins,
proteomics and antibody technology. The CAT/OGS Protein Chip project will focus on combining our expertise to explore
the next generation of high throughput proteomics technology. We see the field of analytical proteomics maturing similarly
to genomics. OGS pioneered industrialised proteomics based on 2D gels and mass spectrometry, for discovery of human
proteins. We currently have over 800 patent filings covering disease specific proteins, with the number growing. Our
technology team has used our expertise in proteomics, micro-engineering and informatics, to develop the prototype of an
antibody-based protein detection microarray. The alliance with CAT provides us access to their high throughput antibody
technology to bring our prototype micro arrays to an industrial scale for developing protein chips as screening and
diagnostic tools. We are very pleased to link up with the acknowledged antibody technology expertise at CAT".

David Chiswell, CEO of CAT said, "Understanding the expression, processing, modification and activity of proteins is
fundamental to the development of revolutionary diagnostics, prognostics and therapies for human disease management.
We at CAT believe that antibody-based microarrays will be a core tool for unlocking this understanding. CAT`s extensive
pioneering work on high throughput antibody isolation, which has included the world`s first fully automated, high throughput
antibody selection and screening processes developed three years ago, makes CAT the partner of choice to develop
Protein Chips. Teaming up with the world-leading proteomics expertise at Oxford GlycoSciences is CAT`s first
collaboration designed to help solve the technological and commercial challenges in developing Protein Chips and to
unlock the strategic value in this new market".

Notes to Editors

OGS
OGS is the world`s leading proteomics based drug discovery and development company headquartered in Oxfordshire,
UK, applying its proteomics technology to pharmaceutical research and development. OGS has proteomics collaborations
with a number of major pharmaceutical companies, including programmes with Pfizer in Alzheimer`s disease and
atherosclerosis, with Merck in diabetes, and in respiratory disease with Bayer. OGS also has a proteomics programme
with Pioneer Hi-Bred/DuPont. Furthermore, in a joint venture with the genomics company, Incyte Genomics Inc., OGS is
building expression databases for licence to pharmaceutical companies, to which Astra Zeneca became the first
subscriber in 1999.

OGS has drug discovery programmes in oncology, inflammation, and infectious disease, and a growing clinical and
pre-clinical pipeline. OGT 918 (Vevesca™) is in late stage clinical trials for the treatment of glycolipid storage disease.

CAT
CAT is a UK biotechnology company using its proprietary technologies in fully human monoclonal antibodies for drug
discovery and drug development. Based in Melbourn, 10 miles south of Cambridge, England, CAT currently employs
around 180 people. CAT is listed on the London Stock Exchange, having raised £41m in its IPO in March 1997. A
Secondary Offering in March 2000 raised £93m. CAT has a world leading platform technology for rapidly isolating fully
human monoclonal antibodies using proprietary phage display systems. CAT has an extensive phage display antibody
library, currently incorporating around 100 billion distinct antibodies. This library, forms the basis for the company`s
strategy to develop a portfolio of clinical development programmes and for discovering new drug leads using functional
genomics. Four fully human therapeutic antibodies developed by CAT are at various stages of clinical trials.

CAT has a number of license and collaborative agreements in place with pharmaceutical and biotechnology companies
including: Eli Lilly, Pfizer, BASF Pharma, Genentech, ICOS Corporation, Genetics Institute, Wyeth-Ayerst, Human
Genome Sciences, AstraZeneca and Pharmacia.

Microarrays
A microarray is a chemically modified surface (chip) onto which a high density of probes have been precisely applied in an
ordered manner.

Protein Chip
A protein chip is a chemically modified surface onto which a high density of protein-based probes have been precisely
applied in an ordered manner.

Some important facts that could cause actual results to vary significantly from management`s expectations noted in these
forward looking statements include government approvals, intellectual property positions and costs. OGT 918 is an
investigational drug and has not received approval for marketing in any country.

Gruss,Mathias